For US Healthcare Professionals


Once daily TRYVIO is the first & only dual endothelin receptor antagonist (ERA) to lower blood pressure in combination with other medications for patients with hypertension who are not adequately controlled.

Available Fall 2024

Are you a Healthcare Professional?

Tell us about yourself.

*Required Fields

Enter your mobile number to receive updates via text.

Tell us about yourself.

*Required Fields

Enter your mobile number to receive updates via text.

By clicking “Sign Up”, I confirm that I am a healthcare provider 18 years of age or older and a US resident. I confirm that I would like to receive email communications and text messages about educational programs and resources, products, and services from Idorsia Pharmaceuticals at the email address and mobile number above. I understand that I can opt out at any time.

Please see full SMS Terms & Conditions. Msg frequency varies. Msg and data rates may apply.

Privacy is important to us. To learn more about our use of your information and your rights, please consult our Privacy Policy.


TRYVIO (aprocitentan), in combination with other antihypertensive drugs, is indicated for the treatment of hypertension to lower blood pressure (BP) in patients who are not adequately controlled on other drugs. Lowering BP reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating reduction of risk of these events with TRYVIO.

Important Safety Information
  • TRYVIO can cause major birth defects if used by pregnant patients.
  • In patients who can become pregnant, obtain a negative pregnancy test prior to initiation of TRYVIO and counsel patients to take monthly pregnancy tests during treatment and one month after discontinuation of TRYVIO.
  • To prevent pregnancy, patients who can become pregnant should use acceptable methods of contraception before the start of, during, and for one month after stopping treatment.
  • Because of the risk of birth defects, TRYVIO is only available through a restricted program called the TRYVIO Risk Evaluation and Mitigation Strategy (REMS).

TRYVIO is contraindicated:

  • in pregnancy. TRYVIO can cause fetal harm when administered during pregnancy.
  • in patients who are hypersensitive to aprocitentan or any of its excipients.
Embryo-Fetal Toxicity and TRYVIO REMS

Based on data from animal reproduction studies with endothelin receptor antagonists (ERAs), TRYVIO can cause fetal harm when administered during pregnancy and is contraindicated for use in patients who are pregnant. Exclude pregnancy and ensure use of acceptable contraceptive methods prior to initiation of treatment with TRYVIO. If pregnancy is detected, discontinue TRYVIO.

TRYVIO is available only through a restricted program under a REMS called the TRYVIO REMS because of the risk of embryo-fetal toxicity. Important requirements of the TRYVIO REMS include:

  • Prescribers must be certified with the TRYVIO REMS by enrolling in and completing training.
  • Pharmacies that dispense TRYVIO REMS must be certified with the TRYVIO REMS.

Further information is available at or 1-866-429-8964.


Elevations of aminotransferases and hepatotoxicity are known effects of ERAs, including TRYVIO. Elevations in alanine transaminase (ALT) or aspartate aminotransferase (AST) of greater than 5-fold upper limit of normal (ULN) were observed rarely in patients treated with aprocitentan in the clinical trial, including cases with positive rechallenge. To reduce the risk of potential serious hepatotoxicity, measure serum aminotransferase levels and total bilirubin prior to initiation of treatment and repeat during treatment periodically and as clinically indicated. 

Do not initiate TRYVIO in patients with elevated aminotransferases (>3×ULN) or moderate to severe hepatic impairment. Advise patients with symptoms suggesting hepatotoxicity (nausea, vomiting, right upper quadrant pain, fatigue, anorexia, scleral icterus, jaundice, dark urine, fever, or itching) to immediately stop treatment with TRYVIO and seek medical attention.

If sustained, unexplained, clinically relevant aminotransferase elevations occur, or if elevations are accompanied by an increase in bilirubin >2×ULN, or if clinical symptoms of hepatotoxicity occur, discontinue TRYVIO.

Fluid Retention

Fluid retention and peripheral edema are known effects of ERAs, including TRYVIO. Edema/fluid retention was reported in 9% of TRYVIO-treated patients compared with 18% of patients receiving aprocitentan 25 mg (twice the recommended dose) and 2% on placebo in the clinical trial, requiring additional diuretic use in some patients. Older age and chronic kidney disease are risk factors for edema/fluid retention with TRYVIO. TRYVIO has not been studied in patients with heart failure New York Heart Association stage III-IV, unstable cardiac function, or with NTproBNP ≥500 pg/mL. TRYVIO is not recommended in these patients.

Monitor for signs and symptoms of fluid retention, weight gain, and worsening heart failure. If clinically significant fluid retention develops, treat appropriately, and consider discontinuation of TRYVIO.

Hemoglobin Decrease

Decreases in hemoglobin concentration and hematocrit have occurred following administration of other ERAs and were observed in the clinical trial with TRYVIO. Hemoglobin decreases usually presented early, stabilized thereafter, and were reversible after discontinuation. A decrease in hemoglobin of >2 g/dL from baseline was observed in 7% of patients compared to 1% of placebo patients. A decrease to below 10.0 g/dL was observed in 3% of TRYVIO-treated patients compared to 0 patients taking placebo. Initiation of TRYVIO is not recommended in patients with severe anemia. Measure hemoglobin prior to initiation of treatment and periodically during treatment as clinically indicated.

Decreased Sperm Counts

TRYVIO, like other ERAs, may have an adverse effect on spermatogenesis. Counsel men about potential effects on fertility.


The most common adverse reactions (more frequent than placebo and ≥2% in TRYVIO-treated patients) are edema/fluid retention and anemia.



There are no data on the presence of aprocitentan in human milk, the effects on the breastfed infant, or the effect on milk production. Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with TRYVIO.

Renal Impairment

TRYVIO is not recommended in patients with kidney failure (eGFR<15 mL/min) or on dialysis. Patients with renal impairment are at increased risk of edema/fluid retention.

Hepatic Impairment

TRYVIO is not recommended in patients with moderate and severe hepatic impairment (Child-Pugh class B and C) because these patients may be at increased risk for poor outcomes from hepatotoxicity.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. Please see full Prescribing Information including BOXED Warning and Medication Guide.